Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod in Asymptomatic Metastatic CRPC
NCT00560482Phase 2Completed
- Sponsor
- Active Biotech AB
- Start
- Dec 2007
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tasquinimod in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Active Biotech AB. Started Dec 2007; status: completed.
02
Drugs
tasquinimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00560482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560482.